<DOC>
	<DOCNO>NCT02550054</DOCNO>
	<brief_summary>The main goal trial investigate whether early administration human erythropoietin ( EPO ) preterm infant improve neurodevelopmental outcome 18 month correct age . This study design randomize , double-masked , placebo control multicenter study involve least 312 patient .</brief_summary>
	<brief_title>Erythropoietin Premature Infants Prevent Encephalopathy</brief_title>
	<detailed_description>EPO safely use prevent preterm anemia recent study show neuro-protective effect . Our hypothesis EPO could prevent preterm brain injury reduce rate premature death disability encephalopathy . The aim study include : investigate safety efficacy EPO use 1000u/kg high dose anemia treatment ( 250u/kg ) ; evaluate effect EPO neurodevelopment preterm infant ; detect biological image indicator EPO . Eligible premature infant enrol double-blind , placebo-controlled randomize trial neonatal neurological intensive care unit ( NNICU ) 7 Children 's Hospital 6 province China . Subjects enrol within first 24 hour life randomly assign receive Epo saline vehicle placebo . Standard NICU care provide subject . Pharmacokinetic data , serial brain electrophysiologic imaging exam , circulate inflammatory mediator , biomarkers complication like polycythemia , neutropenia , thrombocytopenia , hypertension , sepsis , hemorrhage , seizure , necrotizing enterocolitis ( NEC ) , persistent ductus arterious ( PDA ) , apnea prematurity , pulmonary haemorrhage , pulmonary hypertension , Prolonged blood coagulation time , retinopathy prematurity ( ROP ) , cardiac arrhythmia , major venous thrombosis , Renal failure treat dialysis , pneumonia , pulmonary airleak chronic lung disease collect established time point study period . At 18 month correct age , subject undergo neurodevelopmental evaluation assess cerebral palsy , Bayley Scores Mental Development Index ( MDI ) use .</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>1 . Birthweight less equal 1500 gram 2 . Less 32 week gestation birth 3 . Less 48 hour life time enrollment 4 . Written inform consent parent guardian 1 . Intrauterine Growth Retardation 2 . Severe Congenital Anomalies adversely affect life expectancy neurodevelopment 3 . Genetic Metabolic Diseases 4 . Seizures within first 24 hour life 5 . Severe neutropenia ( ANC &lt; 500 cells/microL ) within first 24 hour life 6 . Polycythemia ( Hct &gt; 65 % ) within first 24 hour life 7 . Thrombocytopenia ( platelet &lt; 50K cells/microL ) within first 24 hour life 8 . Hypertension ( SBP &gt; 100mmHg ) without vasopressor support within first 24 hour life 9 . Microcephaly 10 . Grade IIIIV intracranial hemorrhage Termination 1 . Required parent guardian ; 2 . Polycythemia blood transfusion relieve 3 . Oliguria（ &lt; 0.5mL/kg/h least 24 hours） 4 . Progression azotemia 5 . Pulmonary hypertension Cardiac arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>48 Hours</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>